Electronic health record characterization and outcomes of heart failure with preserved ejection fraction.

BACKGROUND: Electronic health record (EHR)-based identification of heart failure with preserved ejection fraction (HFpEF) in the clinical setting may facilitate screening for clinical trials by improving the understanding of its epidemiology and outcomes; yet, previous data have yielded variable results. We sought to characterize groups identified with HFpEF by different EHR screening strategies and their associated long-term outcomes across a large and diverse population. METHODS: We retrospectively analyzed 116,499 consecutive patients from an academic referral center who underwent echocardiography, and 9,263 patients who underwent echocardiography within 6 months of right heart catheterization (RHC), between 2008 and 2018. EHR-based screening strategies identified patients with HFpEF using 1) International Classification of Diseases (ICD)-9/10 codes, 2) H2FpEF score ≥6 and ejection fraction (EF) ≥50%, or 3) RHC wedge pressure ≥15 mmHg and EF ≥50%, when available. Primary outcomes were 1) cumulative incident heart failure hospitalization (HFH), and 2) death, over 10 years. RESULTS: There were 33,461 (29%) patients who met either ICD or H2FpEF-HFpEF definition, of whom 5,310 (16%) met both criteria. Compared to ICD-HFpEF, patients with H2FpEF-HFpEF were more likely older (median age 72 vs 67), White (78% vs 64%), and had atrial fibrillation (97% vs 41%). Among those also with RHC, 6,353 (69%) patients met any HFpEF criteria, of whom only 783 (12%) satisfied all three criteria. Female sex was more common among RHC-HFpEF (55%) compared to other methods (H2FpEF-HFpEF, 47%; ICD-HFpEF, 43%). Atrial fibrillation was substantially higher among HFpEF identified by the H2FpEF score (97%) compared to other methods (49% for ICD and 47% for RHC). Across HFpEF screening methods, 10-year cumulative incidence rates for HFH was 32% to 45% for echocardiography only and 43% to 52% for echocardiography and RHC populations; 10-year risk of death was 54% to 56% for echocardiography only and 52% to 57% for echocardiography and RHC populations. CONCLUSIONS: Different EHR-based HFpEF definitions identified cohorts with modest overlap and varying baseline characteristics. Yet, long-term risk for HFH and death were similarly high for cohorts identified among both populations undergoing echocardiography only or echocardiography and RHC. These data aid in identifying relevant subgroups in clinical trials of HFpEF.

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.

BACKGROUND: Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. The aim of this trial was to assess the effects of switching to riociguat from PDE5i therapy versus continued PDE5i therapy in patients with PAH at intermediate risk of 1-year mortality. METHODS: Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) was an open-label, randomised controlled trial in 81 hospital-based pulmonary hypertension centres in 22 countries. The study enrolled patients aged 18-75 years with symptomatic PAH at intermediate risk of 1-year mortality (based on the European Society for Cardiology-European Respiratory Society guideline thresholds for WHO functional class and 6-min walk distance [6MWD]) who were receiving treatment with a PDE5i with or without an endothelin receptor antagonist for at least 6 weeks before randomisation. Patients were excluded if they had been previously treated with riociguat, had used prostacyclin analogues or prostacyclin receptor agonists within 30 days before randomisation, had clinically significant restrictive or obstructive parenchymal lung disease, or had left heart disease. Patients were randomly assigned (1:1) to remain on PDE5i treatment (oral sildenafil [≥60 mg per day] or oral tadalafil [20-40 mg per day]; the PDE5i group) or to switch to oral riociguat (up to 2·5 mg three times per day; the riociguat group), using an interactive voice and web response system, stratified by cause of PAH. The primary endpoint was clinical improvement by week 24, defined as an absence of clinical worsening and prespecified improvements in at least two of three variables (6MWD, WHO functional class, and N-terminal prohormone of brain natriuretic peptide), analysed using last observation carried forward in all randomly assigned patients with observed values at baseline and week 24 who received at least one dose of study medication (the full analysis set). Secondary endpoints included clinical worsening events. The trial has been completed and is registered with ClinicalTrials.gov, NCT02891850. FINDINGS: Between Jan 11, 2017, and July 31, 2019, 293 patients were screened, of which 226 patients were randomly assigned to the riociguat group (n=111) or to the PDE5i group (n=115). 211 patients completed the study and 14 patients discontinued (seven in each group). One patient assigned to the PDE5i group did not receive treatment, so 225 patients were included in the safety analysis, and one further patient in the PDE5i group had missing components of the composite primary endpoint at baseline, so 224 patients were included in the full analysis set. The primary endpoint was met by 45 (41%) of 111 patients in the riociguat group and 23 (20%) of 113 patients in the PDE5i group; odds ratio [OR] 2·78 (95% CI 1·53-5·06; p=0·0007). Clinical worsening events occurred in one (1%) of 111 patients in the riociguat group (hospitalisation due to worsening PAH) and 10 (9%) of 114 patients in the PDE5i group (hospitalisation due to worsening PAH [n=9]; disease progression [n=1]; OR 0·10 [0·01-0·73]; p=0·0047). The most frequently occurring adverse events were hypotension (15 [14%]), headache (14 [13%]), and dyspepsia (10 [9%]) in the riociguat group, and headache (eight [7%]), cough (seven [6%]), and upper respiratory tract infection (seven [6%]) in the PDE5i group. Serious adverse events were reported in eight (7%) of 111 patients in the riociguat group and 19 (17%) of 114 patients in the PDE5i group. During the study, four patients died in the PDE5i group, one of them during the safety follow-up period. INTERPRETATION: Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway, could be a strategic option for treatment escalation in patients with PAH at intermediate risk of 1-year mortality. FUNDING: Bayer AG, Merck Sharp & Dohme.

Detecção de infarto do miocárdio através de ressonância magnética cardiovascular e angiotomografia coronária em pacientes usuários de cocaína com história de dor torácica após seu uso / Assessment of myocardial infarction by cardiovascular magnetic resonance and computed tomography angiography in patients with cocaine-associated chest pain

INTRODUÇÃO: A cocaína é a terceira droga ilícita mais comumente utilizada nos Estados Unidos e a principal responsável pelo atendimento de pacientes usuários de drogas em serviços de emergência médica. A queixa mais comum na entrada da emergência é a dor torácica, referida em 40% dos casos. Além disso, o uso crônico leva a piora da hipertensão, hipertrofia ventricular esquerda e acelera a aterosclerose. A ressonância magnética cardiovascular é um excelente método para avaliação da morfologia e função ventricular, com excelente reprodutibilidade, e atualmente considerada padrão ouro. A angiotomografia coronária é um método diagnóstico em ascensão, permitindo a detecção de DAC obstrutiva e não obstrutiva, acrescentando informação para a estratificação de risco cardiovascular. O objetivo desse estudo foi avaliar a eventual presença de infarto prévio em pacientes jovens (18 a 40 anos) usuários de cocaína, que apresentavam dor torácica, através da detecção de fibrose miocárdica por exame de ressonância magnética cardiovascular. O objetivo secundário foi avaliar alterações parietais e obstruções das coronárias desses pacientes por angiotomografia coronária. MÉTODOS: Avaliamos 24 pacientes usuários de cocaína (nas formas inalatória, injetável ou crack) que apresentavam dor torácica freqüente e de longa duração relacionada ao seu uso. Esses pacientes realizaram a angiotomografia coronária e a ressonância magnética cardiovascular. A angiotomografia coronária avaliou o escore de cálcio e árvore coronária por segmentos, e a ressonância magnética cardiovascular avaliou dimensões, volumes e função ventricular, bem como a eventual presença de realce tardio miocárdico. RESULTADOS: Foram estudados 24 pacientes, 22 homens, com idade média de 29,7 anos (18 a 40 anos). A grande maioria dos pacientes (79%) fazia uso de cocaína inalatória de forma freqüente e 71% dos pacientes já haviam usado crack. O escore de cálcio foi positivo em apenas um paciente [54 (Agatston)...

INTRODUCTION: Cocaine is the third most commonly used illicit drug in the United States and the leading cause of emergency department visits among drug users. Chest pain is the most common cocaine-related presentation, being reported in 40% of patients. Its chronic use causes hypertensive crises, myocardium hypertrophy and accelerates the process of atherosclerosis. Cardiovascular magnetic resonance provides an accurate assessment of cardiac morphology and ventricular function with excellent reproductibility, and it is considered the gold standard method. Computed tomography angiography has emerged as a powerful tool to evaluate patients with suspected coronary artery disease at the same time that it helps in the prognostic assessment of the patient. The purpose of this study was to evaluate the incidence of previous myocardial infarction among young cocaine users (18 to 40 years) with chest pain related with the use of the drug by the assessment of myocardial fibrosis through cardiovascular magnetic resonance. Secondarily, was also meant the evaluation of the coronary tree by the computed tomography angiography. METHODS: We studied 24 cocaine users (crystalline, powder or granular forms) that frequently complained about chest pain related to the use of the cocaine. These patients underwent computed tomography angiography with assessment of calcium score and the evaluation of the segmented coronary arteries, and cardiovascular magnetic resonance to assess dimensions, volumes and ventricular function of the heart, and the presence of myocardial fibrosis. RESULTS: We studied 24 patients (22 male), mean age of 29.7 years. Most of the patients (79%) had frequently used inhalatory cocaine, 71% of them had also used the crack cocaine form. The calcium score turned out to be positive in only one patient [54 (Agatston) and 56 (volume)]. None of them showed significant coronary stenosis. Among the coronary segments evaluated, only one patient had calcified...

[Angioedema related to the use of streptokinase]. / Angioedema relacionado ao uso de estreptoquinase.

Angioedema is a rare reaction to streptokinase, acute and potentially fatal, which should be quickly diagnosed and treated to guarantee the best prognosis for the patient. We describe here the case of a 65-year-old man, who displayed an anaphylactic reaction after the beginning of thrombolysis with streptokinase, which was quickly treated, and remained hospitalized for one week in the Intensive Care Unit.

Angioedema relacionado ao uso de estreptoquinase / Angioedema related to the use of streptokinase

O angioedema é uma reacão rara, aguda e potencialmente fatal, à estreptoquinase, devendo ser diagnosticada prontamente e tratada para garantir melhor prognóstico ao paciente. Descrevemos aqui o caso de um homem de 65 anos, que apresentou reacão anafilática após o início de trombólise com estreptoquinase, sendo rapidamente tratado, permaneceu uma semana internado em Unidade de Terapia Intensiva.

Acidentes com crianças e sua evolução na região de Campinas, SP / Accidents with children in the region of Campinas, Brazil

Objetivos: Avaliar prospectivamente acidentes em unidades hospitalar, deterninando as causas mais freqüentes, com a finalidade de estabelecer bases para programas de prevenção. Métodos: O estudo abrangeu de março de 1997 a fevereiro de 1998. Todas as crianças até 14 anos vítimas de acidente tiveram seus dados de entrada anotados em ficha padronizada. Resultados: Foram atendidas 3.214 crianças vítimas de acidentes, representando 11,4 por cento do total. Predominou o sexo masculino (62,1 por cento). Os acidentes foram mais freqüêntes entre 9 e 13 anos (33,4 por cento), 2 e 5 anos (27,2 por cento) e 5 a 9 anos (25,5 por cento). Em 74 por cento houve traumatismo, devido principalmente quedas. O TCE foi importante nos menores de 1 ano, e o de membros entre 9 e 13 anos. Picadas e mordeduras ocorreram predominantemente entre os 5 e 13 anos e as intoxicações exógenas e acidentes com corpo estranho 2 e 5 anos. As queimaduras, entre os menores de 5 anos. 89,7 por cento dos atendimentos foram de baixa complexidade, mas 20 pacientes foram encaminhados para a UTI e ocorreram 4 óbitos em sala de emergência. Conclusões: A criança acima de 9 anos, menino, com traumatismo de membros por queda foi o caso de acidente mais freqüente. Programas de prevenção devem ter como alvo faixas etárias específicas. Os acidentes sobrecarregam serviços terciários com atendimentos de baixa complexidade. É necessário habilitar os centros de atenção primária para os casos de baixa complexidade